Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease

Interventions: Drug: Sirolimus
Drug: Cyclophosphamide
Drug: Alemtuzumab
Drug: Busulfan
Biological: Pheripheral blood stem cells
Drug: Tociluzumab
Drug: Emapalumab-Izsg
Drug: Total Body Irradiation

First Posted Date: 2022-07-18

Last Posted Date: 2024-10-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT05463133

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Relapsed or Refractory Large B-cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Dexamethasone

First Posted Date: 2022-07-15

Last Posted Date: 2024-10-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 30

Registration Number: NCT05459571

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 13 locations

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

First Posted Date: 2022-07-14

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 435

Registration Number: NCT05457556

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 59 locations

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
Grade 3b Follicular Lymphoma
High Grade B-Cell Lymphoma

Interventions: Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Biological: Retifanlimab
Biological: Rituximab and Hyaluronidase Human
Biological: Tafasitamab
Drug: Vincristine
Procedure: Bone Marrow Aspiration
Procedure: Multigated Acquisition Scan
Other: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Biospecimen Collection
Drug: Polatuzumab Vedotin

First Posted Date: 2022-07-13

Last Posted Date: 2024-11-20

Lead Sponsor: University of Washington

Target Recruit Count: 35

Registration Number: NCT05455697

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Biological: Rituximab
Biological: Tafasitamab
Drug: Vincristine
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Lumbar Puncture
Procedure: Biospecimen Collection

First Posted Date: 2022-07-12

Last Posted Date: 2024-04-23

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT05453500

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1

Active, not recruiting

Conditions: Mesothelioma
Mesothelioma, Malignant
Ovarian Cancer
Pancreatic Cancer
TNBC - Triple-Negative Breast Cancer
Ovarian Adenocarcinoma
Ovarian Neoplasms
Mesotheliomas Pleural
Colorectal Cancer
Triple Negative Breast Cancer

Interventions: Biological: TC-510
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-07-11

Last Posted Date: 2024-03-06

Lead Sponsor: TCR2 Therapeutics

Target Recruit Count: 6

Registration Number: NCT05451849

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

and more 4 locations